MedCity News October 14, 2021
Elise Reuter

The startup shared results of a prospective study showing its deep learning software detected melanoma with 93% sensitivity and 91% specificity.

Not long after Paige cinched FDA clearance for its algorithm to flag potentially cancerous lesions, another digital pathology startup is touting the results of a study claiming its deep learning technology can detect melanoma with a high degree of accuracy.

Philadelphia-based Proscia shared the results of a prospective study testing its DermAI software on skin biopsies from two different laboratories. It found that its AI detected melanoma in situ and invasive melanoma with a sensitivity of 93% and a specificity of 91%.

Proscia has not yet published the results of the prospective study, but it hopes to move...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: AI (Artificial Intelligence), Provider, Survey / Study, Technology, Trends
March Fundraising Roundup: 7 Provider Tech Startups That Closed Rounds This Month
Google DeepMind unveils ‘superhuman’ AI system that excels in fact-checking, saving costs and improving accuracy
Katie Couric Talks Colon Cancer, Health Equity And AI
5 tips on AI adoption from a frontline physician champion
Survey of Oncologists Finds Agreement, Concerns Over AI Use

Share This Article